Skip to search formSkip to main contentSkip to account menu

moxifloxacin

Known as: 1-cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid, MOXI 
A fluoroquinolone antibiotic with antibacterial activity. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and… 
National Institutes of Health

Related topics

Related topics

39 relations
AmiodaroneAmiodarone hydrochlorideAvelox 400 mg oral tablet includes Avelox ABC PackBacterial Infections

Broader (3)

Anti-Bacterial AgentsFluoroquinolonesTopoisomerase II Inhibitors

Narrower (5)

AveloxMoxifloxacin hydrochlorideOctegraProflox

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
Importance In December 2019, novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) occurred in Wuhan, China. The number of… 
Highly Cited
2014
Highly Cited
2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
BACKGROUND Early-phase and preclinical studies suggest that moxifloxacin-containing regimens could allow for effective 4-month… 
Highly Cited
2014
Highly Cited
2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
BACKGROUND Tuberculosis regimens that are shorter and simpler than the current 6-month daily regimen are needed. METHODS We… 
Highly Cited
2011
Highly Cited
2011
BDDCS Applied to Over 900 Drugs
Here, we compile the Biopharmaceutics Drug Disposition Classification System (BDDCS) classification for 927 drugs, which include… 
Highly Cited
2009
Highly Cited
2009
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
RATIONALE Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and in a mouse model of antituberculosis… 
Review
2007
Review
2007
Bacteroides: the Good, the Bad, and the Nitty-Gritty
  • H. Wexler
  • Clinical Microbiology Reviews
  • 2007
  • Corpus ID: 30170463
SUMMARY Summary: Bacteroides species are significant clinical pathogens and are found in most anaerobic infections, with an… 
Highly Cited
2006
Highly Cited
2006
Inhibitors of NF-κB signaling: 785 and counting
Nuclear factor kappa B (NF-κB) transcription factors regulate several important physiological processes, including inflammation… 
Highly Cited
2005
Highly Cited
2005
An epidemic, toxin gene-variant strain of Clostridium difficile.
BACKGROUND Recent reports suggest that the rate and severity of Clostridium difficile-associated disease in the United States are… 
Highly Cited
2004
Highly Cited
2004
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.
Tuberculosis continues to be a major cause of morbidity and mortality in the world. The expansion of tuberculosis control… 
Highly Cited
2004
Highly Cited
2004
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
BACKGROUND Moxifloxacin is a quinolone antimicrobial that has potent activity against Mycobacterium tuberculosis. To optimize… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)